Clinical development of CAR T cell therapy in China: 2020 update.

Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2020 Sep 30;: Authors: Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W Abstract Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative reference for colleagues in the field, and a better understanding of the history and current situation will help us more reasonably conduct research and promote cooperation. PMID: 32999455 [PubMed - as supplied by publisher]
Source: Cellular and Molecular Immunology - Category: Molecular Biology Authors: Tags: Cell Mol Immunol Source Type: research